The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
11 天
Verywell Health on MSNSpravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder, ...
17 天
GlobalData on MSNJ&J’s Spravato receives FDA label expansion for depression monotherapyJohnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not respond to ...
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
4 天
Inquirer on MSNWorld’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
It is available only through a restricted REMS program. The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果